LINC00619: A Potential Drug Target Or Biomarker (G414260)

Target Name: LINC00619

NCBI ID: G414260

LINC00619

Other Name(s): C10orf136 | Long intergenic non-protein coding RNA 619 | long intergenic non-protein coding RNA 619 | bA168P8.1

LINC00619: A Potential Drug Target Or Biomarker

LINC00619 (C10orf136) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and biology have made it an attractive target for researchers to study and potentially develop new treatments.

The LINC00619 molecule is composed of 19 exons that encode a protein with 619 amino acid residues. The protein is predicted to have a molecular weight of 79.9 kDa and a calculated pI of 6.1 Angstroms. It is expressed in a variety of tissues and cells, including muscle, heart, brain, and various cell types.

One of the key features of LINC00619 is its ability to interact with other proteins. It has been shown to form a complex with the protein FBN1, which is a critical factor in blood clotting. This interaction between LINC00619 and FBN1 has led to the hypothesis that LINC00619 may be a regulator of blood clotting and may be a potential drug target for thrombosis.

Another potential mechanism by which LINC00619 may be involved in disease is its role in neurodegenerative diseases. The structure and expression of LINC00619 have been shown to be altered in a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These changes in the LINC00619 molecule have led to the assumption that it may be involved in the development and progression of these diseases.

In addition to its potential role in neurodegenerative diseases, LINC00619 has also been shown to be involved in cancer. The expression and function of LINC00619 have been altered in a variety of cancer types, including breast cancer, lung cancer, and colorectal cancer. These changes have led to the assumption that LINC00619 may be a potential drug target for cancer.

The potential drug targets for LINC00619 are vast and varied. Its ability to interact with other proteins and its role in various diseases make it an attractive target for researchers to study and develop new treatments. One potential approach to targeting LINC00619 is to use small molecules to modulate its expression and activity. This approach has been used to study the effects of various small molecules on LINC00619 expression and function in cell culture models of disease.

Another approach to targeting LINC00619 is to use antibodies to block its function. The use of antibodies to block the interaction of LINC00619 with other proteins, such as FBN1, has been shown to be effective in cell culture models of disease. This approach has the potential to be used in animal models of disease and eventually in human clinical trials.

In conclusion, LINC00619 is a non-coding RNA molecule that has the potential to be a drug target or biomarker for a variety of diseases. Its unique structure and biology, as well as its ability to interact with other proteins, make it an attractive target for researchers to study and develop new treatments. Further research is needed to fully understand the role of LINC00619 in disease and to develop effective therapies based on its unique properties.

Protein Name: Long Intergenic Non-protein Coding RNA 619

The "LINC00619 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00619 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets